All In Biotech

Drug Trial Radar · NCT03118570

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)

Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Sep 11, 2017

Primary completion

Oct 1, 2019

Study completion Nov 12, 2020

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma
First posted
Apr 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.

Conditions

  • Osteogenesis Imperfecta, Type I
  • Osteogenesis Imperfecta Type III
  • Osteogenesis Imperfecta Type IV

Interventions

  • setrusumabDrug

    Intravenous infusion

  • CalciumDietary supplement

    tablets

  • Vitamin DDietary supplement

    capsules

  • zoledronic acid (optional)Drug

    Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12Time frame: Baseline, Month 12 (end of treatment [EOT])
  2. Change From Baseline in Radial Bone Strength (Failure Load) at Month 12Time frame: Baseline, Month 12 (EOT)
  3. Change From Baseline in Radial Bone Strength (Stiffness) at Month 12Time frame: Baseline, Month 12 (EOT)

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Mereo Investigator Site

    Birmingham, Alabama

  • Mereo Investigator Site

    Jacksonville, Florida

  • Mereo Investigator Site

    Baltimore, Maryland

  • Mereo Investigator Site

    Boston, Massachusetts

  • Mereo Investigator Site

    Saint Paul, Minnesota

  • Mereo Investigator Site

    St Louis, Missouri

  • Mereo Investigator Site

    Albuquerque, New Mexico

  • Mereo Investigator Site

    Cincinnati, Ohio

  • Mereo Investigator Site

    Portland, Oregon

  • Mereo Investigator Site

    Pittsburgh, Pennsylvania

  • Mereo Investigator Site

    Nashville, Tennessee

  • Mereo Investigator Site

    Houston, Texas

  • Mereo Investigator Site

    Toronto, Ontario, Canada

  • Mereo Investigator Site

    Montreal, Quebec, Canada

  • Mereo Investigator Site

    Québec, Quebec, Canada

  • Mereo Investigator Site

    Aarhus, Denmark

  • Mereo Investigator Site

    Odense, Denmark

  • Mereo Investigator Site

    Lyon, France

  • Mereo Investigator Site

    Paris, France

  • Mereo Investigator Site

    Paris, Paris Cedex 14, France

  • Mereo Investigator Site

    Bristol, United Kingdom

  • Mereo Investigator Site

    London, United Kingdom

  • Mereo Investigator Site

    Cambridge, Cambridgeshire, United Kingdom

  • Mereo Investigator Site

    Newcastle upon Tyne, Newcastle, United Kingdom

  • Mereo Investigator Site

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.